Danske Bank A S Reduces Stock Position in Tenet Healthcare Corporation $THC

Key Points

• Danske Bank cut its stake in Tenet Healthcare by 91.0% in Q4, selling 8,116 shares and leaving 800 shares valued at about $159,000, signaling a notable institutional trim.
• Tenet beat Q1 EPS ($4.82 vs. $4.21 estimate) and raised FY‑2026 guidance to 16.38–18.68 EPS, supporting the recent rally despite margin pressure from payer mix and rising costs.
• Company insiders have sold heavily (46,517 shares worth roughly $10.94M in the past 90 days), while analysts hold a consensus "Moderate Buy" with an average price target near $244, presenting mixed signals for investors.

Danske Bank A S decreased its position in Tenet Healthcare Corporation (NYSE:THC - Free Report) by 91.0% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 800 shares of the company's stock after selling 8,116 shares during the quarter. Danske Bank A S's holdings in Tenet Healthcare were worth $159,000 at the end of the most recent quarter.

A number of other hedge funds also recently bought and sold shares of THC. GenTrust LLC grew its position in shares of Tenet Healthcare by 15.2% in the 4th quarter. GenTrust LLC now owns 5,076 shares of the company's stock worth $1,009,000 after buying an additional 670 shares during the last quarter. Sigma Planning Corp lifted its stake in Tenet Healthcare by 6.3% in the fourth quarter. Sigma Planning Corp now owns 3,568 shares of the company's stock worth $709,000 after acquiring an additional 212 shares during the period. Citizens Financial Group Inc. RI bought a new stake in Tenet Healthcare in the fourth quarter valued at $210,000. Activest Wealth Management bought a new position in Tenet Healthcare in the 4th quarter worth $26,000. Finally, Torren Management LLC bought a new stake in shares of Tenet Healthcare during the 4th quarter valued at about $52,000. Hedge funds and other institutional investors own 95.44% of the company's stock.

Key Headlines Impacting Tenet Healthcare

Here are the key news stories impacting Tenet Healthcare this week:

• Positive Sentiment: Q1 beat and raised guidance: Tenet topped Q1 EPS estimates as admissions and ambulatory growth drove results, and the company raised its FY‑2026 EPS outlook — a clear catalyst supporting the rally even as management flagged payer‑mix pressure and rising costs that compressed margins. THC Beats Q1 Earnings Estimates on Strong Ambulatory Growth, Ups '26 EPS View
• Positive Sentiment: Analyst support: RBC Capital reaffirmed its Buy stance on THC, which reinforces investor confidence that the company’s growth story remains intact. RBC Capital Sticks to Their Buy Rating for Tenet Healthcare (THC)
• Positive Sentiment: Investor narrative & momentum: Recent Zacks pieces highlight THC as a trending and high‑growth name (ambulatory expansion, above‑average financial growth), which can attract momentum flows and retail attention. Here is What to Know Beyond Why Tenet Healthcare Corporation (THC) is a Trending Stock Tenet (THC) is an Incredible Growth Stock: 3 Reasons Why
• Neutral Sentiment: Analyst / market commentary roundup: The Globe & Mail ran an analysts'‑insights piece covering Tenet alongside peers — useful for context but not an immediate catalyst. Analysts Offer Insights on Healthcare Companies: Tenet Healthcare (THC) and Kymera Therapeutics (KYMR)
• Neutral Sentiment: Market commentary & valuation discussion: Several outlets (Yahoo, Zacks) are debating whether THC’s multi‑year rally leaves upside limited — important for positioning but mixed impact on price. Is It Too Late To Consider Tenet Healthcare (THC) After Its Strong Multi‑Year Rally?
• Neutral Sentiment: Compensation disclosure: Coverage summarizing CEO pay over the last five years is informational (governance/ESG interest) but not an immediate price mover. Tenet CEO pay in the last 5 years
• Negative Sentiment: Analyst downgrades & price target cuts: Robert W. Baird cut its price target to $210 and moved to a Neutral rating, trimming upside expectations; Stephens also cut its target to $260 — analyst mark‑downs can limit near‑term upside. Baird price target cut / coverage Tenet Healthcare NYSE: THC Price Target Cut to $260.00 by Analysts at Stephens
• Negative Sentiment: Quality/reputational risk: A Tenet executive commented publicly on a Leapfrog grade gap and broader issues “beyond 1 lawsuit,” which could raise investor concern about quality metrics, regulatory scrutiny, or reputation risk. Tenet executive on Leapfrog’s spring 2026 grade gap: ‘This goes way beyond 1 lawsuit’

Wall Street Analysts Forecast Growth

Several analysts have commented on THC shares. TD Cowen restated a "buy" rating on shares of Tenet Healthcare in a report on Thursday, February 12th. Weiss Ratings restated a "buy (b-)" rating on shares of Tenet Healthcare in a research note on Friday, March 27th. Royal Bank Of Canada reduced their price target on Tenet Healthcare from $277.00 to $236.00 and set an "outperform" rating on the stock in a research note on Friday, May 1st. Barclays lowered their price objective on Tenet Healthcare from $257.00 to $238.00 and set an "overweight" rating for the company in a research report on Tuesday. Finally, Jefferies Financial Group upped their target price on shares of Tenet Healthcare from $250.00 to $265.00 and gave the stock a "buy" rating in a research report on Thursday, February 12th. Nineteen research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $244.16.

Insider Buying and Selling at Tenet Healthcare

In other news, insider R. Scott Ramsey sold 8,017 shares of the firm's stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $232.70, for a total transaction of $1,865,555.90. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, EVP Paola M. Arbour sold 6,500 shares of the stock in a transaction that occurred on Wednesday, March 11th. The shares were sold at an average price of $238.43, for a total transaction of $1,549,795.00. Following the transaction, the executive vice president owned 29,291 shares in the company, valued at approximately $6,983,853.13. This trade represents a 18.16% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 46,517 shares of company stock worth $10,943,111. Company insiders own 0.81% of the company's stock.

Tenet Healthcare Stock Up 4.0%

NYSE:THC opened at $194.29 on Thursday. The firm has a 50-day simple moving average of $205.68 and a two-hundred day simple moving average of $204.22. Tenet Healthcare Corporation has a fifty-two week low of $146.60 and a fifty-two week high of $247.21. The company has a debt-to-equity ratio of 1.96, a quick ratio of 1.30 and a current ratio of 1.36. The firm has a market cap of $16.74 billion, a P/E ratio of 10.10, a P/E/G ratio of 1.24 and a beta of 1.30.

Tenet Healthcare (NYSE:THC - Get Free Report) last announced its quarterly earnings data on Thursday, April 30th. The company reported $4.82 earnings per share for the quarter, topping analysts' consensus estimates of $4.21 by $0.61. The company had revenue of $5.37 billion during the quarter, compared to analyst estimates of $5.39 billion. Tenet Healthcare had a net margin of 7.94% and a return on equity of 25.55%. The firm's revenue for the quarter was up 2.6% on a year-over-year basis. During the same period in the previous year, the business earned $4.36 EPS. Tenet Healthcare has set its FY 2026 guidance at 16.380-18.68 EPS. Analysts predict that Tenet Healthcare Corporation will post 17.56 earnings per share for the current fiscal year.

About Tenet Healthcare

Tenet Healthcare Corporation NYSE: THC is a diversified American healthcare services company that owns and operates acute care hospitals and a broad range of outpatient facilities. Its portfolio includes general acute-care hospitals, specialty hospitals, ambulatory surgery centers, urgent care and diagnostic imaging centers, and other ancillary service locations. Tenet's operations are oriented around delivering inpatient and outpatient clinical care across multiple medical specialties, with an emphasis on surgical services, emergency care, and advanced diagnostics.

In addition to facility-based care, Tenet provides integrated services designed to support clinical operations and improve patient access and care coordination.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.